Latest News & Updates

Breaking News

  • 4 hours ago

  • Team Pharma Now

Emerging Trends in Personalised Medicine at the PHARMAP 2026 at Amsterdam
Breaking News
Cue Biopharma Reports Positive Preclinical Safety Data For CUE-401 In Autoimmune Development

Vaibhavi M.

Bristol Myers Squibb’s Iberdomide NDA Accepted By FDA For Relapsed Or Refractory Multiple Myeloma, FDA Grants Breakthrough Therapy Designation To Iberdomide

Vaibhavi M.

Pfizer Reports Positive Progression Free Survival Data From BREAKWATER Trial OBRAFTOVI® In BRAF V600E Metastatic Colorectal Cancer

Vaibhavi M.

Essential Pharma Expands Rare Disease Franchise with Ventavis® And Breelib® Acquisition, Strengthening Rare Cardio-Pulmonary Portfolio

Vaibhavi M.

Other trending news you may like to read

Emerging Trends in Personalised Medicine at the PHARMAP 2026 at Amsterdam

PHARMAP 2026 highlights patient-centric packaging and inclusive pharma design in Amsterdam.

Team Pharma Now

Pharma Now

Cue Biopharma Reports Positive Preclinical Safety Data For CUE-401 In Autoimmune Development

Cue Biopharma reports positive preclinical safety and tolerability data for CUE-401 in autoimmune development.

Vaibhavi M.

Pharma Now

Bristol Myers Squibb’s Iberdomide NDA Accepted By FDA For Relapsed Or Refractory Multiple Myeloma, FDA Grants Breakthrough Therapy Designation To Iberdomide

FDA accepts BMS NDA for iberdomide in RRMM and grants Breakthrough Therapy designation.

Vaibhavi M.

Pharma Now

Pfizer Reports Positive Progression Free Survival Data From BREAKWATER Trial OBRAFTOVI® In BRAF V600E Metastatic Colorectal Cancer

Pfizer reports positive PFS data for BRAFTOVI combo in BRAF V600E metastatic colorectal cancer.

Vaibhavi M.

Pharma Now